A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Three Different Doses of BMS-582949 Given Orally to Subjects With Moderate to Severe Plaque Psoriasis.
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2015
At a glance
- Drugs BMS 582949 (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 04 Dec 2015 According to ClinicalTrials.gov record, the trial phase changed from phase I to pahse II.
- 02 Oct 2009 New trial record.